Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Serono Inc, the US affiliate of Switzerland-headquartered biotech firm Serono, has launched Saizen for use in the treatment of patients with adult growth hormone deficiency, following the product's recent FDA approval.
Subscribe to our email newsletter
Clinical trials have demonstrated that adult growth hormone deficiency (AGHD) can be effectively treated with Saizen (somatropin, rDNA origin, for injection).
With the US approval, the treatment is now available to patients who were growth hormone deficient during childhood and have growth hormone deficiency as an adult. In addition, adult patients who have adult onset growth hormone deficiency either alone, or associated with multiple hormone deficiencies, now have access to Saizen and its line of devices.
Saizen can be administered using a needle-free device, named Cool Click, the only FDA approved needle-free device for the administration of growth hormone. It can also be administered with a recently launched autoinjector pen device, One Click, or by traditional needle and syringe.